Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Rituximab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Rituximab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Obinutuzumab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Obinutuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Ofatumumab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Ofatumumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Ublituximab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Ublituximab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Veltuzumab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Veltuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Ocaratuzumab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Ocaratuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Alemtuzumab |
Anti-CD52 mAb | Hematologic (CLL) | ||
|
Molecule
Alemtuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (CLL)
Drug Class / Mechanism
Anti-CD52 mAb |
||||
Elotuzumab |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Elotuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Daratumumab |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Daratumumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Daratumumab + Hyaluronidase (SC) |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Daratumumab + Hyaluronidase (SC)
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Isatuximab |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Isatuximab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
RituximabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
ObinutuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
OfatumumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
UblituximabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
VeltuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
OcaratuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
AlemtuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (CLL)
Drug Class / Mechanism
Anti-CD52 mAb |
|
ElotuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
DaratumumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
Daratumumab + Hyaluronidase (SC)Immunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
IsatuximabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|